F

Formation Bio

AI-driven platform accelerates clinical-stage drug development

Director / Senior Director - Drug Metabolism and Pharmacokinetics

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeHybrid

About the Job

Requirements

  • PhD in pharmaceutical sciences, pharmacokinetics, pharmacology, chemistry, biochemistry, or a related discipline, with typically 8+ years of relevant biotechnology or pharmaceutical industry experience, or an equivalent combination of education and experience.
  • Deep expertise in DMPK with substantial experience supporting development-stage small-molecule programs.
  • Demonstrated experience integrating nonclinical and clinical PK data to guide drug-development decisions.
  • Strong understanding of ADME, clearance mechanisms, drug metabolism, transporters, absorption and bioavailability, protein binding, tissue distribution, and drug-drug interactions.
  • Experience with human PK prediction, PK/PD and exposure-response analysis, and clinical translation.
  • Experience supporting IND-enabling development and clinical-stage programs.
  • Strong working knowledge of regulatory expectations for DMPK and clinical pharmacology during drug development.
  • Experience evaluating complex datasets and making recommendations when information is incomplete, inconsistent, or evolving.
  • Demonstrated ability to work effectively with external CROs, consultants, and partners.
  • Written and verbal communication skills, including the ability to synthesize complex technical information into clear conclusions for non-specialist and senior audiences.

Responsibilities

  • Serve as the DMPK subject-matter expert for scientific diligence of potential in-licensing, acquisition, and partnership opportunities across therapeutic areas and development stages.
  • Evaluate nonclinical and clinical PK, ADME, metabolism, transporter, bioavailability, PK/PD, and exposure-response datasets, collaborating with Clinical Pharmacology, to assess asset strengths, liabilities, and development potential.
  • Assess data quality and completeness, identify gaps or inconsistencies, and distinguish material development risks from issues that can be readily addressed.
  • Evaluate human PK characteristics, dose and exposure projections, therapeutic margins, DDI potential, organ impairment considerations, formulation and absorption issues, and other factors affecting an asset’s clinical profile.
  • Integrate DMPK findings with pharmacology, toxicology, clinical, CMC, and regulatory information to assess assets holistically.
  • Develop decision-oriented recommendations for cross-functional diligence teams and senior leadership, articulating key risks, uncertainties, potential mitigations, and value-creating opportunities.
  • Define priority experiments, analyses, or data requests to resolve critical diligence questions and transition promising assets into the portfolio.
  • Provide DMPK leadership for advanced preclinical and clinical-stage programs and represent DMPK on cross-functional development teams.
  • Develop fit-for-purpose DMPK strategies from late preclinical development through IND/CTA, early clinical development, and subsequent development stages.
  • Integrate in vitro ADME, animal PK, toxicokinetics, clinical PK, pharmacology, biomarker, and safety data to develop a quantitative understanding of exposure and response.
  • Lead human PK prediction and nonclinical-to-clinical PK/PD translation to inform first-in-human dose selection, and partner with Clinical Pharmacology and Pharmacometrics on clinical dose escalation and dose optimization.
  • Partner with Clinical Pharmacology to investigate unexpected or suboptimal clinical PK and develop hypotheses, analyses, and studies to inform program decisions.
  • Partner with Clinical Pharmacology to oversee metabolism, transporter and DDI assessments, metabolite characterization, MIST strategy, mass-balance studies, organ impairment assessments, food-effect studies, and other relevant clinical pharmacology activities.
  • Partner with Clinical Pharmacology, Pharmacometrics, Clinical Development, Toxicology, CMC, and other functions to optimize development plans.
  • Contribute to regulatory strategy and author or critically review relevant sections of INDs, CTAs, briefing documents, and other regulatory submissions.
  • Provide scientific oversight of CROs, consultants, and other external partners conducting DMPK and related studies.
  • Apply informed judgment to ensure the depth and timing of DMPK work fit each program’s maturity, risk, and value.
  • Develop integrated views of DMPK and translational risk to support rapid, high-quality portfolio decisions.
  • Establish and evolve fit-for-purpose DMPK capabilities, external partnerships, analytical approaches, and best practices as the portfolio grows.
  • Communicate complex scientific findings clearly and concisely to multidisciplinary teams and senior leadership.

Desired Qualifications

  • Direct experience supporting first-in-human and subsequent clinical studies is strongly preferred.

About the Company

Formation Bio

AI-driven platform accelerates clinical-stage drug development

Formation Bio uses an AI-driven platform to speed up drug development by focusing on clinical-stage assets. It acquires and advances these assets using flexible financing structures, aiming to shorten timelines and cut costs for bringing new drugs to market. The core product is the proprietary AI tools that help with drug selection, development planning, and improving overall efficiency, enabling partnerships and successful commercialization with pharmaceutical and biotech companies. Compared with competitors, Formation Bio combines a data-powered approach with adaptable financing and asset acquisition strategies to move assets forward quickly and cost-effectively. The goal is to make treatments more accessible and affordable by accelerating development and enabling faster, more predictable commercialization through AI-enhanced decision making and flexible funding options.

Company size
51-200
Company stage
Series D
Total funding
$530.3M
Headquarters
New York City, New York
Founded
2013

Recently Posted Jobs

Explore more opportunities at Formation Bio

See more jobs